Tome Biosciences

Tome Biosciences is a biotechnology company focused on developing programmable genomic integration (PGI) technologies for curative cell and integrative gene therapies. Their PGI technologies allow the precise insertion of any genetic sequence at any location in the genome, enabling the correction of genetic defects and the rewiring of cell circuitry for therapeutic purposes. Tome has a strong team with expertise in gene therapy, drug development, and manufacturing, and they are backed by leading investors in the biotech space.

The company's initial focus is on monogenic liver diseases and autoimmune diseases. For liver diseases, they aim to provide potentially curative treatments with a single drug per disease. For autoimmune diseases, they are developing cell therapies that can be re-dosed and reversed. Tome is working on two core PGI technologies: integrase-mediated PGI (I-PGI) for large DNA sequences and ligase-mediated PGI (L-PGI) for small DNA sequences. Both technologies are showing promising results in preclinical studies and have the potential to revolutionize genomic medicine.

Tome Biosciences does not provide specific information about job flexibility on its website.

Tome Biosciences is a programmable genomic integration (PGI) company focused on developing curative treatments for both rare and common diseases. Their technology enables the insertion of any DNA sequence, of any size, into any location in the genome with site-specific precision. This revolutionary approach allows Tome to write the "final chapter in genomic medicines", delivering cures to patients through cell and integrative gene therapies.

Tome Biosciences promotes a culture of innovation, purpose, and teamwork. They are at the forefront of genome engineering and recognize the responsibility that comes with driving science forward to create cures. They value building an exceptional team to bring their technologies to patients in need, and their commitment to creating a positive work environment is evident in their focus on fostering a culture of collaboration, learning, and growth.

Tome Biosciences recognizes the responsibility that comes with pioneering innovation in genome engineering and strives to build a diverse and inclusive workplace that reflects the communities they serve. Their commitment to fostering a culture of equity is evident in their efforts to attract, develop and retain a diverse workforce. The company seeks to create a welcoming environment where all employees feel valued, respected and empowered to contribute their unique perspectives and talents.